Expression of cyclooxygenase-1 and -2 in naturally occurring squamous cell carcinomas in horses

American Journal of Veterinary Research

Volumn 68, Issue 1, 2007, Pages 76-80

  Elce, Yvonne A ^a   Orsini, James A ^b   Blikslager, Anthony T ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; LIQUID NITROGEN;

ANIMAL TISSUE; ARTICLE; CANCER THERAPY; CARCINOGENESIS; CONJUNCTIVA; CONTROLLED STUDY; EUTHANASIA; EYE CANCER; HORSE DISEASE; NONHUMAN; PENIS CARCINOMA; PREPUCE; PROTEIN EXPRESSION; SPECIES DIFFERENCE; SQUAMOUS CELL CARCINOMA; VULVA CARCINOMA; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; FEMALE; HORSE DISEASES; HORSES; MALE; NEOPLASMS;

ANIMALIA; EQUIDAE; OVIS;

EID: 33846469387     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.68.1.76     Document Type: Article

References (28)

1. Foy JM, Rashmir-Raven AM, Brashier MK. Common equine skin tumors. Compend Contin Educ Pract Vet 2002;24:242-254.
2. May KA, Moll HD, Lucroy MD. Recognizing tumors of the equine external genitalia. Compend Contin Educ Pract Vet 2002;24:970-976.
3. Dugan SJ, Curtis CR, Roberts SM, et al. Epidemiologic study of ocular/ adnexal squamous cell carcinoma in horses. J Am Vet Med Assoc 1991;198:251-256.
4. Brosnahan MM, Paradis MR. Demographic and clinical characteristics of geriatric horses: 467 cases (1989-1999). J Am Vet Med Assoc 2003;223:93-98.
5. Theon AP, Pascoe JR, Meagher DM. Perioperative intratumoral administration of cisplatin for treatment of cutaneous tumors in equidae. J Am Vet Med Assoc 1994;205:1170-1176.
6. Howarth S, Lucke VM, Pearson H. Squamous cell carcinoma of the equine external genitalia: a review and assessment of penile amputation and urethrostomy as a surgical treatment. Equine Vet J 1991;23:53-58.
7. Palmer SE. Treatment of common cutaneous tumors using the carbon dioxide laser. Clin Tech Equine Pract 2002;1:43-50.
8. Theon AP, Pascoe JR, Galuppo LD, et al. Comparison of perioperative versus postoperative intratumoral administration of cisplatin for treatment of cutaneous sarcoids and squamous cell carcinomas in horses. J Am Vet Med Assoc 1999;215:1655-1660.
9. Fortier LA, Mac Harg MA. Topical use of 5-fluorouracil for treatment of squamous cell carcinoma of the external genitalia of horses: 11 cases (1988-1992). J Am Vet Med Assoc 1994,205:1183-1185.
10. May KA, Moll HD, Lucroy MD. Surgical treatment of external genital tumors in horses. Compend Contin Educ Pract Vet 2002;24:570-576.
11. Hendrix DVH. Equine ocular squamous cell carcinoma. Clin Tech Equine Pract 2005;4:87-94.
12. Theon AP, Pascoe JR. Iridium-192 interstitial brachytherapy for equine periocular tumors: treatment results and prognostic factors in 115 horses. Equine Vet J 1994;27:117-121.
13. Moore AS, Beam SL, Rassnick KM, et al. Long-term control of mucocutaneous squamous cell carcinoma and metastases in a horse using piroxicam. Equine Vet J 2003;35:715-718.
14. Pestili de Almeida EM, Piche C, Sirois J, et al. Expression of cyclo-oxygenase-2 in naturally occurring squamous cell carcinomas in dogs. J Histochem Cytochem 2001;49:867-875.
15. Wang D, Mann JR, Dubois RN. The role of prostaglandins and other eicosanoids in the gastrointestinal tract. Gastroenterology 2005;128:1445-1461.
16. El-Sheikh SS, Madaan S, Alhasso A, et al. Cyclooxygenase-2: a possible target in schistoma-associated bladder cancer. BJU Int 2001;88:921-927.
17. Knapp DW, Richardson RC, Chan TCK, et al. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1994;8:273-278.
18. Schmidt BR, Glickman NW, DeNicola DB, et al. Evaluation of piroxicam for the treatment of oral squamous cell carcinoma in dogs. J Am Vet Med Assoc 2001;218:1783-1786.
19. Pollard M, Luckert PH. Prevention and treatment of primary intestinal tumors in rats by piroxicam. Cancer Res 1989;49:6471-6473.
20. Boria PA, Murry DJ, Bennett PF, et al. Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs. J Am Vet Med Assoc 2004;224:388-394.
21. Kawamori T, Rao CV, Siebert K, et al. Chemopreventive activity of Celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998;58:409-412.
22. Knapp DW, Chan TC, Kuczek T, et al. Evaluation of in vitro cytotoxicity of nonsteroidal anti-inflammatory drugs against canine tumor cells. Am J Vet Res 1995;56:801-805.
23. Leahy KM, Ornberg RL, Wang Y, et al. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 2002;62:625-631.
24. Sawaoka H, Tsuji S, Tsujii M, et al. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest 1999;79:1469-1477.
25. 1 deficiency inhibits colon cancer development. Carcinogenesis 2005;26:353-357.
26. Wilson JE, Chandrasekharan NV, Westover KD, et al. Determination of expression of cyclooxygenase-1 and -2 isoenzymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. Am J Vet Res 2004;65:810-818.
27. Tomlinson JE, Wilder BO, Young KM, et al. Effects of flunixin meglumine or etodelac treatment on mucosal recovery of equine jejunum after ischemia. Am J Vet Res 2004;65:761-769.
28. Davies NM, Good RL, Roupe KA, et al. Cyclooxygenase-3: axiom, dogma, anomaly, enigma or splice error? - not as easy as 1, 2, 3. J Pharm Pharmaceut Sci 2004;7:217-226.